ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients

Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.